AB Science reports first-half 2026 loss and cuts trials
AB Science reported a first-half 2026 net loss and said it is revising its clinical plan after a GCP inspection. The company also said it is discontinuing three non-priority studies.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.